Overview
ATOS market data
Price History
ATOS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$4.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.70 – $19.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $24.2 · P/B 1.94 · P/S 151.50.
Company news
Atossa Therapeutics Presents Mechanism-Driven (Z)-Endoxifen Data In McCune-Albright Syndrome At 2026 AACR Special Conference In Cancer ResearchBenzinga · Jul 21, 2026, 12:34 PM
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12Benzinga · Jul 7, 2026, 4:55 PM
Crude Oil Edges Higher; Driven Brands Posts Upbeat EarningsBenzinga · Jun 11, 2026, 3:44 PM
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseBenzinga · Jun 11, 2026, 1:55 PM
Atossa Therapeutics shares are trading lower after the company announced registered direct offering of up to $16.5 million in gross proceeds.Benzinga · Jun 11, 2026, 12:47 PM
Atossa Therapeutics Enters Securities Purchase Agreement With Institutional Investors For 1,363,638 SharesBenzinga · Jun 11, 2026, 12:18 PM
8-K filing — ATOSSA THERAPEUTICS, INC. (ATOS)SEC EDGAR · Jun 11, 2026, 12:00 PM
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · May 26, 2026, 5:15 PM
Atossa Therapeutics Announces Acceptance Of (Z)-Endoxifen DMD Manuscript For Publication In Degenerative Neurological And Neuromuscular DiseaseBenzinga · May 20, 2026, 8:55 PM
Atossa Therapeutics To Host Virtual KOL Event Focused On Evolving Clinical And Translational Data Supporting Development Of (Z)-Endoxifen As Potential Next-Gen Endocrine Therapy Backbone Across Multiple ER-Positive Breast Cancer SettingsBenzinga · May 14, 2026, 12:47 PM